Trial Outcomes & Findings for Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec (NCT NCT02153346)
NCT ID: NCT02153346
Last Updated: 2018-08-17
Results Overview
Participants completed questionnaires within 2 weeks post-recruitment, 4, 8 and 12 months to measure indirect cost of disease, specifically related to productivity. The following questionnaires were used: WPAI helps to determine presenteeism, absenteeism, and total cost calculation (TCC) possible (number of days during the year of study), while VOLP is used to assess the impact of health conditions on lost productivity in monetary units (United states dollars). The following parameters were calculated: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA).
COMPLETED
NA
101 participants
BL and at 12-month FUP
2018-08-17
Participant Flow
Participants (par.) in this cohort study were randomly selected from the BD-Asthma/RESP registry in Quebec, with an asthma diagnosis between June 2014 and January 2015, more than 18 years of age, and followed at the outpatient clinics of Hôpital du Sacré-Coeur de Montréal (HSCM), a tertiary care clinic specialized in asthma.
187 participants were selected in the BD-Asthma/RESP database; 160 were contacted of which 101 participants were enrolled in the study. 59 refused to participate. Participants were not assigned to any investigational therapies.
Participant milestones
| Measure |
BD-Asthma/RESP
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
|
|---|---|
|
Overall Study
STARTED
|
101
|
|
Overall Study
COMPLETED
|
90
|
|
Overall Study
NOT COMPLETED
|
11
|
Reasons for withdrawal
| Measure |
BD-Asthma/RESP
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
|
|---|---|
|
Overall Study
Lost to Follow-up
|
11
|
Baseline Characteristics
Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec
Baseline characteristics by cohort
| Measure |
BD-Asthma/RESP
n=101 Participants
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
|
|---|---|
|
Age, Continuous
|
53.5 Years
STANDARD_DEVIATION 14.0 • n=5 Participants
|
|
Sex: Female, Male
Female
|
65 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
36 Participants
n=5 Participants
|
|
Education
None
|
9 Participants
n=5 Participants
|
|
Education
High school
|
27 Participants
n=5 Participants
|
|
Education
College
|
15 Participants
n=5 Participants
|
|
Education
University
|
41 Participants
n=5 Participants
|
|
Education
missing
|
1 Participants
n=5 Participants
|
|
Smoking habits
Ex-smokers
|
44 Participants
n=5 Participants
|
|
Smoking habits
Current smokers
|
10 Participants
n=5 Participants
|
|
Smoking habits
Never smokers
|
46 Participants
n=5 Participants
|
|
Smoking habits
missing
|
1 Participants
n=5 Participants
|
|
Number of years with asthma
|
20.7 Years
STANDARD_DEVIATION 16.7 • n=5 Participants
|
|
Control
|
1.4 ACQ Score
STANDARD_DEVIATION 0.9 • n=5 Participants
|
|
Age of Asthma onset
|
32.7 Years
STANDARD_DEVIATION 19.1 • n=5 Participants
|
|
FEV1
|
89.3 Percent predicted
STANDARD_DEVIATION 23.0 • n=5 Participants
|
|
FEV1/FVC
|
75.1 Percent
STANDARD_DEVIATION 9.4 • n=5 Participants
|
|
BMI
<18.5
|
3 Participants
n=5 Participants
|
|
BMI
18.5-24.9
|
18 Participants
n=5 Participants
|
|
BMI
25.0-29.9
|
38 Participants
n=5 Participants
|
|
BMI
>=30.0
|
39 Participants
n=5 Participants
|
|
BMI
missing
|
3 Participants
n=5 Participants
|
|
Number of years at the HSCM asthma clinic
|
10.4 years
STANDARD_DEVIATION 9.0 • n=5 Participants
|
|
Asthma severity
Mild
|
1 Participants
n=5 Participants
|
|
Asthma severity
Moderate
|
56 Participants
n=5 Participants
|
|
Asthma severity
Severe
|
26 Participants
n=5 Participants
|
|
Asthma severity
missing
|
18 Participants
n=5 Participants
|
|
Employment Status
Full time
|
37 Participants
n=5 Participants
|
|
Employment Status
Part-time as an employee
|
13 Participants
n=5 Participants
|
|
Employment Status
Self-employed
|
9 Participants
n=5 Participants
|
|
Employment Status
Work disability
|
6 Participants
n=5 Participants
|
|
Employment Status
Unemployed but seeking work
|
1 Participants
n=5 Participants
|
|
Employment Status
Retired
|
35 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: BL and at 12-month FUPPopulation: Source Population: all par. with asthma diagnosed by respirologist and followed at outpatient asthma clinic of the HSCM and registered in BD-Asthma/RESP. Only par. with available data in each category (represented by n=X in the category title) were analyzed. One third of par. selected were retired. Only 59 were active workers (52 at BL; 40 at FUP).
Participants completed questionnaires within 2 weeks post-recruitment, 4, 8 and 12 months to measure indirect cost of disease, specifically related to productivity. The following questionnaires were used: WPAI helps to determine presenteeism, absenteeism, and total cost calculation (TCC) possible (number of days during the year of study), while VOLP is used to assess the impact of health conditions on lost productivity in monetary units (United states dollars). The following parameters were calculated: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA).
Outcome measures
| Measure |
BD-Asthma/RESP
n=52 Participants
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
|
|---|---|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
BL,CPA TCC, n=46
|
18.4 US Dollars
Standard Deviation 82.0
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
BL, CAA, n=52
|
253.3 US Dollars
Standard Deviation 847.5
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
FUP, CAA, n=40
|
70.4 US Dollars
Standard Deviation 157.6
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
BL,CPA,n=50
|
16.9 US Dollars
Standard Deviation 78.8
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
FUP,CPA, n=39
|
17.1 US Dollars
Standard Deviation 37.2
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
BL,CAA TCC, n=46
|
183.3 US Dollars
Standard Deviation 648.2
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
FUP,CAA TCC,n=37
|
76.10 US Dollars
Standard Deviation 162.64
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
FUP,CPA TCC,n=37
|
17.1 US Dollars
Standard Deviation 37.20
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
BL,TICA,n=46
|
201.7 US Dollars
Standard Deviation 723.7
|
|
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)
FUP, TICA, n=37
|
93.2 US Dollars
Standard Deviation 182.3
|
PRIMARY outcome
Timeframe: BL and 12-month FUPPopulation: Source Population. Only participants with available data in each category (represented by n=X in the category title) were analyzed. One third of the participants selected were retired. Only 59 participants were active workers. Therefore the stratification for asthma control and severity included very low numbers (52 at BL; 40 at FUP).
Costs of asthma are greater when the asthma is sub-optimally managed and controlled and varies depending on the par. asthma control. Asthma control was assessed using the Asthma Control Questionnaire (ACQ) and par. were asked to recall their experiences during the previous week and respond to the 6 specified questions on a 7-point Likert scale (0=well-controlled; 6=maximum impairment \[poorly controlled\]; a score of ≤0.75 indicates well controlled symptoms. The following parameters were presented: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA). Only 59 par. were active workers. When stratified by asthma control and severity each stratum had a sample less than 59. Although results are presented. data may not be reliable due to the low number of par. in each stratum.
Outcome measures
| Measure |
BD-Asthma/RESP
n=52 Participants
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
|
|---|---|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Well controlled, CPA TCC, n=14
|
12.65 Canadian Dollars
Standard Deviation 33.74
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Partly controlled, CAA, n=9
|
557.65 Canadian Dollars
Standard Deviation 1380.41
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Partly controlled, CAA, n=10
|
171.66 Canadian Dollars
Standard Deviation 266.70
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Partly controlled, CPA, n=10
|
57.04 Canadian Dollars
Standard Deviation 168.54
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Partly controlled, CPA, n=10
|
32.51 Canadian Dollars
Standard Deviation 50.72
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Partly controlled, CAA TCC, n=8
|
585.29 Canadian Dollars
Standard Deviation 1473.06
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Partly controlled, CAA TCC possible, n=10
|
171.66 Canadian Dollars
Standard Deviation 266.70
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL,Partly controlled, CPA TCC, n=8
|
71.30 Canadian Dollars
Standard Deviation 188.04
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Partly controlled, CPA TCC, n=10
|
32.51 Canadian Dollars
Standard Deviation 50.72
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Partly controlled, TICA, n=8
|
656.59 Canadian Dollars
Standard Deviation 1660.30
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Partly controlled, TICA, n=10
|
204.18 Canadian Dollars
Standard Deviation 296.69
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Uncontrolled, CAA, n=21
|
96.09 Canadian Dollars
Standard Deviation 233.01
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Uncontrolled, CAA, n=15
|
39.75 Canadian Dollars
Standard Deviation 73.72
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Uncontrolled, CPA, n=22
|
9.20 Canadian Dollars
Standard Deviation 34.71
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Uncontrolled, CPA, n=14
|
9.34 Canadian Dollars
Standard Deviation 25.80
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Uncontrolled, CAA TCC, n=20
|
100.89 Canadian Dollars
Standard Deviation 238.00
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Uncontrolled, CAA TCC, n=13
|
45.86 Canadian Dollars
Standard Deviation 77.69
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Uncontrolled, CPA TCC, n=20
|
10.12 Canadian Dollars
Standard Deviation 36.36
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Uncontrolled, CPA TCC, n=10
|
10.06 Canadian Dollars
Standard Deviation 26.71
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Uncontrolled, TICA, n=20
|
111.01 Canadian Dollars
Standard Deviation 239.72
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Uncontrolled, TICA, n=13
|
55.92 Canadian Dollars
Standard Deviation 99.75
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Well controlled, CAA, n=22
|
278.92 Canadian Dollars
Standard Deviation 949.43
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Well controlled, CAA, n=15
|
33.53 Canadian Dollars
Standard Deviation 90.66
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL,Well controlled, CPA, n=18
|
4.02 Canadian Dollars
Standard Deviation 12.84
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Well controlled, CPA, n=15
|
11.8 Canadian Dollars
Standard Deviation 32.68
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL,Well controlled, CAA TCC, n=18
|
96.23 Canadian Dollars
Standard Deviation 251.82
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Well controlled, CAA TCC, n=14
|
35.92 Canadian Dollars
Standard Deviation 93.59
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL, Well controlled, CPA TCC, n=18
|
4.02 Canadian Dollars
Standard Deviation 12.84
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
BL,Well controlled, TICA, n=18
|
100.25 Canadian Dollars
Standard Deviation 263.14
|
|
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP
FUP, Well controlled, TICA, n=14
|
48.57 Canadian Dollars
Standard Deviation 94.44
|
PRIMARY outcome
Timeframe: BL and 12-month FUPPopulation: Source Population. Only participants with available data in each category (represented by n=X in the category title) were analyzed. One third of the participants selected were retired. Only 59 participants were active workers. Therefore the stratification for asthma control and severity included very low numbers (52 at BL; 40 at FUP).
Costs of asthma may vary depending on the participant's asthma severity. Asthma severity was based on the standard definitions for severity and ACQ scores: Mild (\<0.75), Moderate (\>0.75) and Severe (any ACQ score). The following parameters were presented: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA).
Outcome measures
| Measure |
BD-Asthma/RESP
n=52 Participants
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
|
|---|---|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Mild, CAA, n=1
|
154.36 Canadian Dollars
Standard Deviation 0.00
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Mild, CAA, n=1
|
303.74 Canadian Dollars
Standard Deviation 0.00
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Mild, CPA, n=1
|
0.00 Canadian Dollars
Standard Deviation 0.00
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Mild, CPA n=1
|
0.00 Canadian Dollars
Standard Deviation 0.00
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Mild, CAA TCC, n=1
|
154.36 Canadian Dollars
Standard Deviation 0
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Mild, CAA TCC, n=1
|
303.74 Canadian Dollars
Standard Deviation 0
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Mild, TICA, n=1
|
154.36 Canadian Dollars
Standard Deviation 0.00
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Mild, TICA, n=1
|
303.74 Canadian Dollars
Standard Deviation 0.00
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Moderate, CAA, n=30
|
210.09 Canadian Dollars
Standard Deviation 803.66
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Moderate, CAA, n=21
|
67.75 Canadian Dollars
Standard Deviation 160.89
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Moderate, CPA, n=31
|
8.32 Canadian Dollars
Standard Deviation 29.80
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Moderate, CPA, n=19
|
8.62 Canadian Dollars
Standard Deviation 22.19
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Moderate, CAA TCC, n=28
|
67.81 Canadian Dollars
Standard Deviation 139.95
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Moderate, CAA TCC, n=18
|
79.05 Canadian Dollars
Standard Deviation 171.85
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Moderate, CPA TCC, n=28
|
9.21 Canadian Dollars
Standard Deviation 31.28
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Moderate, CPA TCC, n=18
|
9.10 Canadian Dollars
Standard Deviation 22.72
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Moderate, TICA, n=28
|
77.0 Canadian Dollars
Standard Deviation 143.12
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Moderate, TICA, n=18
|
88.14 Canadian Dollars
Standard Deviation 176.35
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Severe, CAA, n=10
|
553.96 Canadian Dollars
Standard Deviation 1319.40
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Severe, CAA, n=7
|
103.16 Canadian Dollars
Standard Deviation 229.93
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Severe, CPA, n=9
|
59.52 Canadian Dollars
Standard Deviation 178.57
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Severe, CPA, n=8
|
27.99 Canadian Dollars
Standard Deviation 54.90
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Severe, CAA TCC, n=8
|
650.38 Canadian Dollars
Standard Deviation 1475.45
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Severe, CAA TCC, n=7
|
103.16 Canadian Dollars
Standard Deviation 229.93
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Severe, CPA TCC, n=8
|
66.96 Canadian Dollars
Standard Deviation 189.40
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Severe, CPA TCC, n=7
|
31.99 Canadian Dollars
Standard Deviation 58.03
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
BL, Severe, TICA, n=8
|
717.35 Canadian Dollars
Standard Deviation 1661.26
|
|
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP
FUP, Severe, TICA, n=7
|
135.16 Canadian Dollars
Standard Deviation 285.08
|
SECONDARY outcome
Timeframe: At BL, 4-Month, 8-Month and 12-Month FUPPopulation: Source Population. Only par. with available data in each category (represented by n=X in the category title) were analyzed. Among the 101 par., 35 (35%) were retired and 59 (58%) were working. Only par. working were who completed the WPAI questionnaire were included in the analysis (56 at BL; 49 at 4 months; 37 at 8 months; 44 at FUP).
WPAI is a self-administered instrument to determine the degree to which asthma affected work productivity while at work and affected activities outside of work in the last 7 days and yields 4 types of scores: Absenteeism (work time missed/missed due to other reasons); Presenteeism (actual time worked); Work Productivity Loss (affected productivity while working); and Activity Impairment (affected regular activities). The following parameters were presented: Hours (Hrs) missed due to asthma (HMA), Hrs missed due to other reasons (HMO), and Hrs actually worked (HAW); all in the last 7 days.
Outcome measures
| Measure |
BD-Asthma/RESP
n=56 Participants
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
|
|---|---|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
BL, HMA, last 7 days, n=56
|
0.4 Hours
Standard Deviation 2.8
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
4-Month FUP, HMA, last 7 days, n=49
|
2.4 Hours
Standard Deviation 9.0
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
8-Month FUP, HMA, last 7 days, n=37
|
0.9 Hours
Standard Deviation 5.3
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
12-Month FUP, HMA, last 7 days, n=44
|
0.0 Hours
Standard Deviation 0.3
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
BL, HMO, last 7 days, n=56
|
3.3 Hours
Standard Deviation 9.0
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
4-Month FUP, HMO, last 7 days, n=49
|
4.2 Hours
Standard Deviation 9.1
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
8-Month FUP, HMO, last 7 days, n=37
|
6.1 Hours
Standard Deviation 12.8
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
12-Month FUP, HMO, last 7 days, n=44
|
4.4 Hours
Standard Deviation 10.5
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
BL, HAW, last 7 days, n=56
|
32.9 Hours
Standard Deviation 13.4
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
4-Month FUP, HAW, last 7 days, n=49
|
27.6 Hours
Standard Deviation 15.8
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
8-Month FUP, HAW, last 7 days, n=37
|
28.1 Hours
Standard Deviation 16.0
|
|
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points
12-Month FUP, HAW, last 7 days, n=44
|
33.0 Hours
Standard Deviation 16.6
|
Adverse Events
BD-Asthma/RESP
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
GSK Response Center
GlaxoSmithKline
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER